Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.

Core Insights - Crinetics Pharmaceuticals has appointed Dr. Robert M. Cuddihy as senior vice president of Medical Affairs, bringing over 30 years of experience in endocrinology and pharmaceutical medical affairs [1][2] - Dr. Cuddihy will play a crucial role in the development and potential commercialization of investigational product candidates, including paltusotine and atumelnant, which target high unmet needs in endocrine diseases [2] - The company is focused on developing novel therapeutics for endocrine diseases and related tumors, with paltusotine in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome, while atumelnant is completing Phase 2 studies for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [3] Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for endocrine diseases [3] - The company's drug candidates are all orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, addressing various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity [3]